CTLA4 and melanoma: One case series of 22 patients treated with tocilizumab (two of whom started treatment prior to receiving ICI) demonstrated a good safety profile and efficacy for the treatment of irAEs in melanoma (related to PD-1, PD-L1, and/or CTLA-4 inhibitors) (49).